Status:
COMPLETED
Synergistic Immunomodulatory Effect of Synbiotics Pre and Postoperative Resection of Pancreatic Ductal Adenocarcinoma
Lead Sponsor:
Theodor Bilharz Research Institute
Conditions:
Pancreatic Ductal Adenocarcinoma
Eligibility:
All Genders
25-65 years
Phase:
PHASE4
Brief Summary
The goal of this interventional study was to evaluate the synergistic effect of symbiotics (a combination of probiotics and prebiotics) compared to probiotics alone in terms of their impact on anti-tu...
Eligibility Criteria
Inclusion
- Patients with primary PDAC with complete pathological and follow-up data
- Patients without long-distance metastasis
- Patients without chronic diseases
- Patients without any treatments before the surgery.
Exclusion
- Patients who suffered from other tumors or other chronic diseases or accidentally died
- Lack of pathological and follow-up data.
- Patients with long-distance metastasis before the surgery.
Key Trial Info
Start Date :
December 12 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 10 2023
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT06199752
Start Date
December 12 2021
End Date
September 10 2023
Last Update
January 10 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sara Maher
Cairo, Egypt, 12411